Net Income

Riding a wave of record sales from its iDose TR implant, Glaukos is set to update investors on its explosive growth and the launch of its new drug, Epioxa.

In a show of strong investor confidence, Gilat secured an oversubscribed $100M private placement, fueling its strategy for major acquisitions in the satcom market.

A new partnership in Northeast Ohio allows health plan members to buy nutritious groceries with a simple card swipe, turning local stores into health hubs.

Falco Resources restructures key debt and names a new board chair, gaining critical runway to advance its massive Horne 5 gold project in Quebec.

Annexus and Athene are embedding complex academic theories into new retirement products. But can they deliver on the promise of safer returns for investors?

AI data firm Hyperscale Data ties its fate to Bitcoin, with a treasury nearing its market value. A bold strategy or a risky gambit amid a major pivot?

Beyond Nordic hype, Helsinki's compact size and collaborative spirit are fostering a unique, accessible, and innovative culinary scene on its own terms.

Vantage's recent triple award win for trust, tech, and social good is more than a trophy. It reveals the new anatomy of a broker's identity.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Ford hits the brakes on its aggressive EV plan, pivoting to profitable hybrids and a bold new venture in battery energy storage. What does this mean?

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Beijing touts its Sanjiangyuan project as a win for ecology and herders. But beyond the state narrative lies a complex story of coercion and cultural risk.

A popular countertop choice is fueling a deadly, incurable lung disease among workers, sparking a public health crisis and a race for safer alternatives.

A new collaboration aims to transform market noise into actionable foresight, moving beyond simple bets to offer a unified view of the global economy.

An ISG report names Rackspace a leader in AI-driven cloud services, revealing how it helps midmarket firms master cost, complexity, and security.